US FDA clears Alzheimer’s drug for early stage treatment: Is this a breakthrough therapy?
This clearance is significant because Donanemab is the only drug that has been able to demonstrate that the treatment can be stopped once the protein plaques clear out. As ...
Indian Express
35 minutes ago